Getinge (OM:GETI B) - Aktienkurs, Nachrichten und Analyse

GETI B Aktienübersicht

Getinge AB (publ) bietet Produkte und Lösungen für Operationssäle, Intensivstationen und Sterilisationsabteilungen. Mehr Details

GETI B grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	5/6
Künftiges Wachstum	4/6
Vergangene Leistung	2/6
Finanzielle Gesundheit	6/6
Dividenden	4/6

Belohnungen

55.7% unter unserer Schätzung des beizulegenden Zeitwerts gehandelt

Prognostiziertes Gewinnwachstum 22.02% pro Jahr

Im Vergleich zu Wettbewerbern und der Branche gut bewertet

Risikoanalyse

Unbeständige Dividendenentwicklung

Die Gewinnspannen (5%) sind niedriger als im Vorjahr (7.4%)

Getinge AB (publ) Wettbewerber

Elekta

OM:EKTA B

SEK 24.1b

Arjo

OM:ARJO B

SEK 9.2b

CellaVision

OM:CEVI

SEK 5.4b

Elos Medtech

OM:ELOS B

SEK 5.7b

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Getinge
Historische Aktienkurse
Aktueller Aktienkurs	SEK 172.65
52-Wochen-Hoch	SEK 240.20
52-Wochen-Tief	SEK 171.35
Beta	0.49
11 Monat Veränderung	-13.31%
3 Monate Veränderung	-14.82%
1 Jahr Veränderung	-21.67%
33 Jahre Veränderung	-57.43%
5 Jahre Veränderung	2.40%
Veränderung seit IPO	393.29%

Aktuelle Nachrichten und Updates

Getinge (STO:GETI B) Is Experiencing Growth In Returns On Capital

Oct 17

Recent updates

An Intrinsic Calculation For Getinge AB (publ) (STO:GETI B) Suggests It's 49% Undervalued

Aug 08

Getinge AB (publ) Just Recorded A 21% EPS Beat: Here's What Analysts Are Forecasting Next

Jul 21

We Like These Underlying Return On Capital Trends At Getinge (STO:GETI B)

Jun 27

Getinge (STO:GETI B) Seems To Use Debt Quite Sensibly

May 11

Results: Getinge AB (publ) Exceeded Expectations And The Consensus Has Updated Its Estimates

Apr 25

Is Getinge AB (publ) (STO:GETI B) Trading At A 41% Discount?

Apr 15

The Getinge AB (publ) (STO:GETI B) Annual Results Are Out And Analysts Have Published New Forecasts

Mar 30

Getinge's (STO:GETI B) Upcoming Dividend Will Be Larger Than Last Year's

Mar 29

The Return Trends At Getinge (STO:GETI B) Look Promising

Mar 21

Analysts Are Updating Their Getinge AB (publ) (STO:GETI B) Estimates After Its Full-Year Results

Feb 04

There's Reason For Concern Over Getinge AB (publ)'s (STO:GETI B) Price

Jan 20

Here's Why Getinge (STO:GETI B) Can Manage Its Debt Responsibly

Jan 05

Getinge AB (publ)'s (STO:GETI B) Intrinsic Value Is Potentially 42% Above Its Share Price

Dec 20

Returns On Capital Are Showing Encouraging Signs At Getinge (STO:GETI B)

Dec 05

Getinge (STO:GETI B) Has A Pretty Healthy Balance Sheet

Oct 06

Is There An Opportunity With Getinge AB (publ)'s (STO:GETI B) 37% Undervaluation?

Sep 21

Getinge's (STO:GETI B) Returns On Capital Are Heading Higher

Sep 03

Is Getinge (STO:GETI B) A Risky Investment?

Jun 28

Is There An Opportunity With Getinge AB (publ)'s (STO:GETI B) 23% Undervaluation?

Jun 15

Investors Will Want Getinge's (STO:GETI B) Growth In ROCE To Persist

Jun 01

At kr252, Is Getinge AB (publ) (STO:GETI B) Worth Looking At Closely?

May 05

Getinge (STO:GETI B) Has Announced That It Will Be Increasing Its Dividend To SEK4.25

Apr 05

Slowing Rates Of Return At Getinge (STO:GETI B) Leave Little Room For Excitement

Feb 28

Is Getinge AB (publ) (STO:GETI B) Trading At A 42% Discount?

Feb 16

Getinge (STO:GETI B) Is Paying Out A Larger Dividend Than Last Year

Feb 04

Is Getinge (STO:GETI B) Using Too Much Debt?

Feb 03

When Should You Buy Getinge AB (publ) (STO:GETI B)?

Jan 07

Are Investors Undervaluing Getinge AB (publ) (STO:GETI B) By 49%?

Nov 06

Getinge (STO:GETI B) Has A Pretty Healthy Balance Sheet

Oct 07

We Think Getinge (STO:GETI B) Can Stay On Top Of Its Debt

Jun 25

Aktionärsrenditen

	GETI B	SE Medical Equipment	SE Markt
7D	-9.6%	-1.8%	-2.8%
1Y	-21.7%	-2.0%	13.4%

Rendite im Vergleich zur Industrie: GETI B unter dem Niveau der Branche Swedish Medical Equipment , die im vergangenen Jahr eine Rendite von -2% erzielte.

Rendite vs. Markt: GETI B hinter dem Markt Swedish zurück, der im vergangenen Jahr eine Rendite von 13.4 erzielte.

Preisvolatilität

Is GETI B's price volatile compared to industry and market?
GETI B volatility
GETI B Average Weekly Movement	3.7%
Medical Equipment Industry Average Movement	7.3%
Market Average Movement	5.5%
10% most volatile stocks in SE Market	11.3%
10% least volatile stocks in SE Market	3.3%

Stabiler Aktienkurs: GETI B hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.

Volatilität im Zeitverlauf: GETI BDie wöchentliche Volatilität (4%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1904	11,848	Mattias Perjos	www.getinge.com

Getinge AB (publ) bietet Produkte und Lösungen für Operationssäle, Intensivstationen und Sterilisationsabteilungen an. Das Unternehmen ist in den Segmenten Acute Care Therapies, Life Science und Surgical Workflows tätig. Es bietet extrakorporale Membranoxygenierung, mechanische Beatmung, mechanische Kreislaufunterstützung, fortschrittliche Patientenüberwachung, ICU-Infrastrukturausrüstung, Patientenflussmanagement und Drainagelösungen.

Getinge AB (publ)'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Getinge im Vergleich zum Marktanteil des Unternehmens?
GETI B grundlegende Statistiken
Marktanteil	SEK 47.02b
Gewinn(TTM)	SEK 1.69b
Umsatz(TTM)	SEK 33.59b

27.8x

Kurs-Gewinn-Verhältnis

1.4x

Kurs-Umsatz-Verhältnis

Ist GETI B zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
GETI B Gewinn- und Verlustrechnung (TTM)
Einnahmen	SEK 33.59b
Kosten der Einnahmen	SEK 18.21b
Bruttogewinn	SEK 15.39b
Sonstige Ausgaben	SEK 13.69b
Umsatz	SEK 1.69b

Zuletzt gemeldete Gewinne

Sep 30, 2024

Datum des nächsten Gewinnberichts

Jan 28, 2025

Gewinn per Aktie (EPS)	6.21
Bruttomarge	45.80%
Nettogewinnspanne	5.03%
Schulden/Eigenkapital-Verhältnis	30.0%

Wie hat sich GETI B auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Dividenden

2.5%

Aktuelle Dividendenrendite

71%

Ausschüttungsquote

GETI B Aktienübersicht

Belohnungen

Risikoanalyse

Getinge AB (publ) Wettbewerber

OM:EKTA B

SEK 24.1b

OM:ARJO B

SEK 9.2b

OM:CEVI

SEK 5.4b

OM:ELOS B

SEK 5.7b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Getinge Appoints Alexandra Holland Executive Vice President of Communications, Effective November 11, 2024

Independent Director recently bought kr473k worth of stock

Consensus EPS estimates fall by 11%

Non-Independent Director recently bought kr621k worth of stock

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Getinge (STO:GETI B) Is Experiencing Growth In Returns On Capital

Recent updates

Getinge Appoints Alexandra Holland Executive Vice President of Communications, Effective November 11, 2024

Independent Director recently bought kr473k worth of stock

Consensus EPS estimates fall by 11%

Non-Independent Director recently bought kr621k worth of stock

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Getinge (STO:GETI B) Is Experiencing Growth In Returns On Capital

Independent Director recently bought kr1.1m worth of stock

Here's Why Getinge (STO:GETI B) Can Manage Its Debt Responsibly

Getinge AB (publ) (OM:GETI B) completed the acquisition of Paragonix Technologies, Inc. from Signet Healthcare Partners.

Independent Chairman recently bought kr4.3m worth of stock

Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire Paragonix Technologies, Inc. from Signet Healthcare Partners for approximately $480 million.

Pinning Down Getinge AB (publ)'s (STO:GETI B) P/E Is Difficult Right Now

An Intrinsic Calculation For Getinge AB (publ) (STO:GETI B) Suggests It's 49% Undervalued

Getinge AB (publ) Just Recorded A 21% EPS Beat: Here's What Analysts Are Forecasting Next

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Getinge AB (publ) to Report Q2, 2024 Results on Jul 18, 2024

We Like These Underlying Return On Capital Trends At Getinge (STO:GETI B)

Investor sentiment deteriorates as stock falls 18%

Getinge (STO:GETI B) Seems To Use Debt Quite Sensibly

Results: Getinge AB (publ) Exceeded Expectations And The Consensus Has Updated Its Estimates

Getinge AB (publ) Declares A Dividend, Payable on 29 April 2024

Upcoming dividend of kr4.40 per share

Is Getinge AB (publ) (STO:GETI B) Trading At A 41% Discount?

The Getinge AB (publ) (STO:GETI B) Annual Results Are Out And Analysts Have Published New Forecasts

Getinge's (STO:GETI B) Upcoming Dividend Will Be Larger Than Last Year's

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Getinge AB (publ) to Report Fiscal Year 2024 Results on Jan 28, 2025

The Return Trends At Getinge (STO:GETI B) Look Promising

Dividend increased to kr4.40

Getinge AB (publ) to Report Fiscal Year 2023 Final Results on Mar 27, 2024

Getinge AB (Publ) Proposes Dividend, Payable on April 29, 2024

Getinge Takes A Leap Forward in Cardiovascular Surgery with the 510(k) Clearance for Vasoview Hemopro 3

Analysts Are Updating Their Getinge AB (publ) (STO:GETI B) Estimates After Its Full-Year Results

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Getinge AB (Publ) Provides Sales Guidance for the Year 2024

Getinge Announces CFO Changes

There's Reason For Concern Over Getinge AB (publ)'s (STO:GETI B) Price

Here's Why Getinge (STO:GETI B) Can Manage Its Debt Responsibly

Price target increased by 8.4% to kr229

Getinge AB (publ)'s (STO:GETI B) Intrinsic Value Is Potentially 42% Above Its Share Price

Returns On Capital Are Showing Encouraging Signs At Getinge (STO:GETI B)

Price target increased by 7.0% to kr220

Consensus EPS estimates increase by 23%

Third quarter 2023 earnings: Revenues exceed analyst expectations

Getinge AB (publ) (OM:GETI B) acquired Healthmark Industries Company, Inc. for $320 million.

Getinge (STO:GETI B) Has A Pretty Healthy Balance Sheet

Is There An Opportunity With Getinge AB (publ)'s (STO:GETI B) 37% Undervaluation?

Getinge AB (Publ) Announces Resignation of Jeanette Hedén Carlsson as Executive Vice President Brand & Communication, Effective December 31, 2023

Getinge's (STO:GETI B) Returns On Capital Are Heading Higher

Second quarter 2023 earnings: Revenues exceed analyst expectations

Getinge Receives US FDA 510(K) Clearance for Servo-Air® Lite

Is Getinge (STO:GETI B) A Risky Investment?

Consensus EPS estimates fall by 13%

Investor sentiment deteriorates as stock falls 22%

Is There An Opportunity With Getinge AB (publ)'s (STO:GETI B) 23% Undervaluation?

Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire High Purity New England Inc. for approximately $290 million.

Investors Will Want Getinge's (STO:GETI B) Growth In ROCE To Persist

At kr252, Is Getinge AB (publ) (STO:GETI B) Worth Looking At Closely?

First quarter 2023 earnings: Revenues exceed analyst expectations

Erträge & Einnahmen